CONGRESS ABSTRACT

Background: In patients with suspected amyloid cardiomyopathy (CM) and a monoclonal protein, tissue biopsy is mandatory to exclude amyloid light-chain CM (AL-CM), the subtype requiring urgent therapy. We aimed to develop a pragmatic approach to estimate the most likely final diagnosis before biopsy. Methods: We studied a multicenter cohort…

Background: Treatment options for cardiac amyloidosis (CA) are rapidly expanding. Therapies suppressing further amyloid accumulation may enable partial amyloid reabsorption; emerging monoclonal antibodies may further enhance amyloid clearance. Myocardial fibrosis, triggered by cardiac injury and amyloid deposition, may be less reversible. Fibrosis data in CA remain limited and mostly…

Introduction Tafamidis is the cornerstone therapy for transthyretin amyloid cardiomyopathy (ATTR-CM); however, validated criteria for monitoring disease progression in treated patients are still lacking. Emerging evidence from untreated cohorts suggests that increases in NT-proBNP levels and outpatient diuretic intensification (ODI) may represent markers of progression. Objectives To evaluate all-cause…

Background: Cardiac amyloidosis (CA) is a systemic infiltrative disease often associated with musculoskeletal manifestations. Orthopedic "red flags" include carpal tunnel syndrome (CTS), lumbar spinal stenosis, and spontaneous rupture of the distal biceps tendon. While their role in early suspicion is established, the association between the presence of these orthopedic…

Background: Speckle-tracking echocardiography (STE) has been increasingly used to uncover subtle cardiac dysfunction in patients with extracardiac sarcoidosis (ECS) who show no clinical evidence of heart disease. However, prior investigations were mostly retrospective, methodologically heterogeneous, and focused primarily on left ventricular (LV) function. We conducted a prospective study to…

Background: Heart failure (HF) is frequently associated with central apnea (CA) and obstructive apnea (OA), which often improve after treatment. Amyloid transthyretin (TTR) cardiomyopathy (ATTR-CM) is increasingly recognized as a cause of HF. Tafamidis, a TTR stabilizer, slows disease progression by preventing TTR misfolding and aggregation, reducing mortality, cardiovascular…